NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

What I understood Dr. Liau to be saying is that the recognized mesenchymal, classical, etc, subgroups are not able to discern in time to select a given therapy for GBM. I believe that leaves only methylated vs un-methylated. I also believe that was the only subgroup called out in advance.

I heard them say they had setup multiple ways to win, but methylated/not was the only subgroup I remember being mentioned.

Back when these things were being talked about often, the greater group learned whether methylation status (I assume of the tumor) is easily measurable in time to select a therapy. My vague recollection is that it is... but asking anyone if they remember for certain.

Does anyone know why it is (as Dr. Liau stated) that the (Mesenchymal etc.) subgroup status cannot be discerned in time to make a therapy selection?

Not saying they will not pass for all GBM in the trial, but just talking about the fall back positions not being as numerous as I had assumed for many years, according to LL's recent statements.